Wegovy pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

• Almost a third of adults taking Wegovy pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 clinical trial¹.
  
  
• Nearly eight in 10 people with poor physical function who took the Wegovy pill almost doubled their ability to move, including bending over, standing comfortably and staying active, compared to placebo².
  
  
• The ORION indirect treatment comparison and the OPTIC patient preference studies, now published (abstract) at the European Congress on Obesity, demonstrated that Wegovy pill provides greater weight loss than orforglipron and has lower odds of stopping medication due to side effects^3-5.
  
  

Bagsværd, Denmark, 13 May 2026 – Novo Nordisk today presented new sub-analyses from the phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 (ECO2026) in Istanbul, Türkiye, showing how well Wegovy pill (oral semaglutide 25 mg) works in adults living with obesity compared with placebo^1,2.

The new findings show that nearly one in three adults (28.8%) who responded early to the Wegovy pill – meaning ≥10% weight loss by week 16 – achieved 13.2% weight loss by week 16 of treatment¹. This group of Wegovy pill early responders went on to achieve 21.6% weight loss by the end of the trial (week 64), while people who did not meet the ‘early response’ criteria still went on to achieve 11.5% weight loss¹. This meant that both groups achieved clinically meaningful weight loss by the end of the trial¹.

“It is important for patients and healthcare professionals to understand that there are differences in the early rapidity of weight loss following initiation of treatment with oral semaglutide 25 mg, and how this can signal the longer-term degree of weight loss that may be achieved," said Prof. W. Timothy Garvey, MD, Department of Nutrition Sciences, University of Alabama at Birmingham. "While the clear majority of patients can expect clinically significant weight loss, these data can be helpful in managing dose escalation, patient expectations and the achievement of treatment goals.”

In addition to substantial weight loss, a separate analysis of the OASIS 4 trial, also presented at ECO2026, showed that when taking Wegovy pill, nearly eight in 10 people who had poor physical function achieved clinically meaningful changes in function scores (77.3% vs 42.9% in the placebo group)². These scores assess aspects of physical function such as range of motion and stamina⁶. This group of people also achieved similar weight loss to that seen in the overall Wegovy pill group².